[Treatment of advanced Hodgkin lymphoma]

Dtsch Med Wochenschr. 2013 Jun;138(23):1212-4. doi: 10.1055/s-0033-1343209. Epub 2013 May 29.
[Article in German]
No abstract available

MeSH terms

  • Amenorrhea / chemically induced
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bleomycin / administration & dosage
  • Bleomycin / adverse effects
  • Brentuximab Vedotin
  • Cause of Death
  • Climacteric / drug effects
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Dacarbazine / administration & dosage
  • Dacarbazine / adverse effects
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Drug Administration Schedule
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Female
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / mortality
  • Hodgkin Disease / pathology
  • Humans
  • Immunoconjugates / administration & dosage
  • Immunoconjugates / adverse effects
  • Molecular Targeted Therapy
  • Neoplasm Staging
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Procarbazine / administration & dosage
  • Procarbazine / adverse effects
  • Vinblastine / administration & dosage
  • Vinblastine / adverse effects
  • Vincristine / administration & dosage
  • Vincristine / adverse effects

Substances

  • Immunoconjugates
  • Bleomycin
  • Procarbazine
  • Vincristine
  • Vinblastine
  • Etoposide
  • Dacarbazine
  • Brentuximab Vedotin
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • ABVD protocol
  • BEACOPP protocol